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Review
Hydroxychloroquine in rheumatic autoimmune
disorders and beyond
Eliise Laura Nirk, Fulvio Reggiori & Mario Mauthe*
Abstract
Initially used as antimalarial drugs, hydroxychloroquine (HCQ) and,
to a lesser extent, chloroquine (CQ) are currently being used to
treat several diseases. Due to its cost-effectiveness, safety and effi-
cacy, HCQ is especially used in rheumatic autoimmune disorders
(RADs), such as systemic lupus erythematosus, primary Sjögren’s
syndrome and rheumatoid arthritis. Despite this widespread use in
the clinic, HCQ molecular modes of action are still not completely
understood. By influencing several cellular pathways through dif-
ferent mechanisms, CQ and HCQ inhibit multiple endolysosomal
functions, including autophagy, as well as endosomal Toll-like
receptor activation and calcium signalling. These effects alter
several aspects of the immune system with the synergistic conse-
quence of reducing pro-inflammatory cytokine production and
release, one of the most marked symptoms of RADs. Here, we
review the current knowledge on the molecular modes of action of
these drugs and the circumstances under which they trigger side
effects. This is of particular importance as the therapeutic use of
HCQ is expanding beyond the treatment of malaria and RADs.
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Introduction
Antimalarial drugs have a long history, starting around 400 years ago
when quinine, a substance in the bark of the cinchona tree, was first
used to fight Plasmodium falciparum infections (Woodward & Doer-
ing, 1945; Haładyj et al, 2018). CQ was the first potent and mass-
producible drug against malaria and was synthesized as an analogue
of quinine (Shanks, 2016). Despite its remarkable antimalarial effi-
ciency, CQ was deemed too toxic due to its side effects such as
gastrointestinal and skin complications, retinopathy, cardiotoxicity or
myopathy (Kalia & Dutz, 2007; Haładyj et al, 2018). The discovery of
HCQ mitigated this issue, and HCQ is now regularly used in clinics
under the brand name Plaquenil (Furst, 1996; Aviña-Zubieta et al,
1998; Al-Bari, 2014; Haładyj et al, 2018). Already during the Second
World War, the positive effects of these two antimalarial drugs on
RADs were observed. Soldiers taking CQ and HCQ as prophylaxis
reported improvement of rashes and inflammatory arthritis. Today,
CQ and particularly HCQ are commonly used to treat rheumatic and
dermatological diseases, and are further being tested in clinical trials
as potential drug candidates for COVID-19, several types of cancer,
diabetes type I and II, multiple sclerosis, recurrent miscarriages and
myocardial infarction (Al-Bari, 2014; clinicaltrials.gov).
RADs, such as systemic lupus erythematosus (SLE) (Ruiz-Iras-
torza et al, 2010; Willis et al, 2012; Wu et al, 2017), rheumatoid
arthritis (RA) (Khraishi & Singh, 1996) and primary Sjögren’s
syndrome (pSS) (Oxholm et al, 1998; Rihl et al, 2009; Kumar &
Clark, 2012; Demarchi et al, 2017), are caused by a malfunctioning
immune system that targets healthy tissues (Smith & Germolec,
1999) such as joints (Kumar & Clark, 2012). CQs and HCQs thera-
peutic role in RADs is linked to its anti-inflammatory and
immunomodulatory effects (Plantone & Koudriavtseva, 2018).
These effects are achieved through the modulation of the autoim-
mune response by (i) impairing functions of the endolysosomal
system through its lysosomotropic effects (Ziegler & Unanue, 1982;
Kaufmann & Krise, 2007; Yoon et al, 2010), (ii) decreasing the levels
of circulating pro-inflammatory cytokines (Sperber et al, 1993; Van
Den Borne et al, 1997), (iii) inhibiting T-cell proliferation (Landewe
et al, 1995; Costedoat-Chalumeau et al, 2014), (iv) blocking Toll-
like receptors (TLRs) (Kyburz et al, 2006) and (v) autophagy inhibi-
tion (An et al, 2017c). However, numerous questions remain
regarding both the mechanism of action of CQ and HCQ in RADs
and the side effects caused by this compound.
In this review, we report on HCQ and CQ modes of action at the
molecular and cellular levels in the context of RADs. Additionally,
we discuss the relevance of these drugs in the treatment of cancer
and infectious diseases. Finally, we summarize the side effects
reported in patients taking HCQ for RADs and discuss how some of
those can be explained by the current knowledge on CQ and HCQ.
CQ and HCQ: modes of action
So far, CQ and HCQ have been reported to inhibit four sets of cellu-
lar functions: (i) endolysosomal activities, including autophagy; (ii)
cytokine signalling, including endosomal Toll-like receptor (TLRs);
(iii) NADPH oxidase (NOX) signalling; and (iv) calcium (Ca2+)
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mobilization from the endoplasmic reticulum (ER). They might
further modulate other cellular and organismal processes, e.g. Golgi
trafficking (Mauthe et al, 2018), but the underlying mechanisms
remain to be identified.
Inhibition of lysosomal activity and autophagy
CQ and HCQ are weak bases that easily cross cell membranes and
accumulate in acidic subcellular compartments such as lysosomes
and endosomes, where they remain trapped in a protonated state
(Ohkuma & Poole, 1978). This leads to a pH increase in lysosomes
from 4 to 6, causing inhibition of acidic proteases and other
enzymes within the endolysosomal compartments (Fig 1A)
(Ohkuma & Poole, 1978; Poole & Ohkuma, 1981; Ziegler & Unanue,
1982; Haładyj et al, 2018). As a result, antigen processing and
subsequent presentation by MHC-II complex on the cell surface of
both macrophages and lymphoid dendritic cells are impaired (Gui-
dos et al, 1984; Chesnut & Grey, 1985; Fox, 1993), dampening the
adaptive immune response (Fig 2) (Fox, 1993). CQ and HCQ also
increase pH levels within the Golgi stacks. This causes functional
alterations of this organelle that possibly contribute to the cellular
effects of these two drugs, e.g. by impairing transforming growth
factor beta (TGF-b) activity (Perkett et al, 2006; Rivinoja et al, 2009;
Mauthe et al, 2018).
The ability to block lysosomal degradation also makes CQ and
HCQ potent macroautophagy inhibitors (Fig 1A). Macroautophagy,
hereafter called autophagy, is a conserved intracellular degradation
pathway that is required to maintain cellular homeostasis by recy-
cling damaged or unwanted cytoplasmic proteins, complexes and
organelles (Eskelinen & Saftig, 2009). Autophagy plays a role in
many physiological processes, and its misregulation is linked to
pathologies such as cancer, neurodegeneration and inflammatory
diseases (Mizushima et al, 2008; Levine et al, 2011; Dikic & Elazar,
2018; Levine & Kroemer, 2019). During autophagy, cytoplasmic
cargoes are sequestered by double-membrane vesicles called
autophagosomes, which fuse with lysosomes to generate autolyso-
somes (Eskelinen & Saftig, 2009). Fusion with lysosomes and activ-
ity of the lysosomal enzymes are required to break down the
autophagosomal cargoes and recycle the resulting metabolites.
Impairment of both autophagosome–lysosome fusion and lysosomal
degradative activity blocks autophagy (Klionsky et al, 2016).
Although CQ and HCQ decrease the acidity of lysosomes (Seglen
et al, 1979; Poole & Ohkuma, 1981; Mizushima et al, 2010), the
Glossary
Antigen-presenting cells (APC)
Cells that process proteins derived from pathogens or from dying/
dead cells, into peptides that get presented on their surface, thereby
activating T cells and initiating an immune response.
Autophagy
An intracellular process that delivers unwanted cytoplasmic material
into lysosome for degradation.
B cells
A type of lymphocytes (white blood cells) that plays a crucial role in
the adaptive immune response by producing antigen-specific
antibodies.
Calcium (Ca2+)
Is the most abundant mineral in the human body and is vital for a
multitude of cellular and physiological function. It is also an
important second messenger in numerous signal transduction
pathways.
Chloroquine (CQ)/hydroxychloroquine (HCQ)
Originally developed to fight malaria, these drugs are used to treat
rheumatic autoimmune diseases and are currently tested in clinical
trials as therapies for other conditions.
Cytokines
Small secreted proteins that mediate communication and modulate
interactions between cells, including immune cells.
Endosomes
Intracellular organelles that mainly function as a sorting and
recycling hub for endocytosed and biosynthetic components, on their
route to lysosomes.
Immune system
A network consisting of a variety of different cell types that defend
the body against infections and other potentially harmful anomalies,
and which, when misregulated, contributes or causes the
development of an inflammatory disease.
Lysosome
Intracellular organelles containing a large battery of digestive
enzymes that degrade extracellular and cytoplasmic material
delivered to their interior by endocytosis and autophagy, respectively.
NADPH oxidase
A membrane-bound multi-subunit enzymatic complex at either the
plasma or endosomal membrane, which participates in a variety of
cellular functions, ranging from cellular signalling and gene
expression to host defence mechanisms.
Primary Sjögren’s syndrome
An autoimmune disease that belongs to the group of rheumatic
autoimmune diseases, which affect saliva-producing glands leading to
symptoms such as dry mouth and dry eyes.
Retinopathy
Condition characterized by a damaged retina, which causes vision
impairment, and is a documented adverse effect that can occur when
taking HCQ and CQ.
Rheumatic autoimmune diseases
A group of conditions characterized by a dysregulated immune
system, which primarily affect the muscles, joints, connective tissue
and bones.
Systemic lupus erythematosus
An autoimmune disease that belongs to the group of rheumatic
autoimmune diseases, which is the most common form of lupus and
is associated with symptoms such as severe fatigue, joint pain and
joint swelling.
T cells
A type of lymphocytes (white blood cells) that is a key component of
the adaptive immune system and that orchestrates other cell types in
response to antigens.
Toll-like receptors (TLR)
Transmembrane proteins that recognize specific molecules at either
the plasma membrane or endosomes, and subsequently initiate
signalling pathways that are crucial for the innate immune response.
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primary inhibitory effect of these drugs on autophagy is blocking
the fusion of autophagosomes and lysosomes, which is at least in
part mediated by the dysregulation of the recruitment of specific
SNARE proteins onto autophagosomes (Mauthe et al, 2018). This
block results in an accumulation of autophagosomes in the cyto-
plasm (Mauthe et al, 2018), which can contribute to an enhanced
autophagosome-mediated signalling output (Martinez-Lopez et al,
2013; Barrow-McGee et al, 2016) and even compromise tumour cell
viability (Button et al, 2017). Although HCQ and CQ have been
extensively described as autophagy inhibitors, there is emerging
evidence that these drugs induce a non-canonical form of endocyto-
sis (Florey et al, 2015; Jacquin et al, 2017).
Inhibition of cytokine signalling
Activation of TLRs, especially in macrophages, monocytes and T
helper cells, but also in neutrophils and endothelial cells, induces
the production and secretion of pro-inflammatory cytokines, a hall-












































Figure 1. Molecular mechanisms of CQ and HCQ.
(A) CQ and HCQ are weak bases that accumulate inside acidic subcellular compartments, e.g. endosomes and lysosomes. They remain trapped in a protonated state, causing
an increase of pH and thereby inhibiting the functions of these cellular compartments. Impairment of the autophagosome–lysosome fusion leads to autophagy inhibition.
(B) CQ and HCQ alter endosomal TLR activation by increasing endosomal pH, by blocking the interaction between nucleic acids and endosomal TLRs (TRL3, TLR7 and TLR9) and
by preventing translocation of TLR8 to endosomes. HCQ also blocks the correct assembly of the NOX2 complex by preventing the translocation of the NOX2 subunit gp91phox
onto endosomes and consequently the formation of an active NOX2. (C) CQ and HCQ impair the release of Ca2+ from the ER, resulting in inhibition of Ca2+-dependent
signalling pathways. HCQ further inhibits the replenishing of intracellular Ca2+ stores from the extracellular space.
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Kim & Moudgil, 2017). Hence, inhibition of endosomal TLRs by
HCQ or CQ is a powerful therapy approach for these diseases (Lafy-
atis et al, 2006). TLR9, activated by DNA in immune cells, can thus
be inhibited by HCQ and CQ (Yi et al, 1998; Ahmad-Nejad et al,
2002). TLR7, activated by guanosine analogues, can also be inhib-
ited by CQ, but to a lesser extent than TLR9 (Lee et al, 2003), indi-
cating different inhibitory mechanisms. TLR3 is mainly activated by
poly(I-C), but also by debris originating from necrotic synovial fluid
cells in RA patients, and both modes of activation are hampered by
HCQ and CQ (Brentano et al, 2005; Jolly et al, 2014; Imaizumi et al,
2017). In general, inhibition of TLR3, TLR7 and TLR9 by HCQ and
CQ has been attributed to their ability to impair endosomal acidifi-
cation (Macfarlane & Manzel, 1998; Lafyatis et al, 2006; Schrezen-
meier & Dörner, 2020), as activation of endosomal TLRs and
subsequent downstream signalling only takes place within acidified
compartments (Fig 1B) (Blasius & Beutler, 2010).
Beside endosomal acidification, Kuznik and colleagues discov-
ered a second mechanism by which CQ impairs TLR signalling.
They showed that CQ could inhibit endosomal TLR signalling after
stimulation with nucleic acids at concentration too low to influence
the endosomal pH. Under those conditions, CQ blocks endosomal
TLR activation by directly interacting with TLR ligands, such as
nucleic acids, which changes the nucleic acid secondary structure
and prevents their binding to endosomal TLRs (Macfarlane &
Manzel, 1998; Kuznik et al, 2011). This notion is further supported
by the observation that HCQ specifically blocks activation of
dendritic cells and macrophages by DNA but not by LPS, although
LPS also stimulates these cells via a signalling cascade emanating
from endosomes (Häcker et al, 1998).
A third mechanism that interferes with inflammatory cytokine
production is the ability to disrupt GMP-AMP synthase (cGAS)
signalling (An et al, 2015, 2018). cGAS is a crucial component of
the cGAS–stimulator of interferon gamma (IFN) genes (STING)
signalling cascade that is required for the IFN type I response in
immune cells (Sun et al, 2013), making it an important player in
activation of pro-inflammatory response in autoimmune diseases
(Gao et al, 2015; Kato et al, 2018). cGAS is also upregulated in a
portion of SLE patients (An et al, 2017a,b), and interestingly, HCQ
and CQ can inhibit cGAS binding to its ligands, e.g. DNA, in vitro
and in a T-cell line (An et al, 2015). Importantly, inhibition of cGAS
activation results in reduced IFNb expression (An et al, 2015)
(Fig 1C).
Inhibition of NADPH oxidase
NOX is a protein complex involved in numerous pro-inflammatory
signalling cascades, such as tumour necrosis factor alpha (TNFa)-
and interleukin (IL)-1b-induced cascades. Activation of endosomal
NOX, which leads to the generation of reactive oxygen species
(ROS), requires the endocytic internalization and delivery to endo-
somes of cell surface ligand–receptor complexes (Müller-Calleja
Decrease levels of circulating pro-inflammatory cytokines
























Figure 2. Effects of HCQ on the immune system.
At the cellular level, HCQ inhibits antigen presentation, B- and T-cell activation and NOX signalling. In addition, it rebalances Treg/Th17 cell ratio. These multifaceted effects on
different immune cells result in a decreased production and release of pro-inflammatory cytokines.
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et al, 2017). HCQ blocks the NOX-mediated signalling cascades trig-
gered by TNFa and IL-1b in monocytes by blocking translocation of
gp91phox, the catalytic subunit of NOX, from the cytosol onto endo-
somal membranes without changing the endosomal pH (Müller-
Calleja et al, 2017). This inhibition prevents the correct assembly
and activation of NOX, hindering the downstream cellular events
and the production of the pro-inflammatory cytokines TNFa and IL-
8. HCQ also prevents the redistribution of TLR8 from the ER to
endosomes, which is necessary to mediate the inflammatory
response (Müller-Calleja et al, 2017) (Fig 1B).
Inhibition of Ca2+ signalling
Ca2+ mobilization from both the ER and extracellular space into the
cytoplasm and subsequent Ca2+-dependent signalling is an impor-
tant mechanism to activate cells of the immune system, such as T
and B cells (Feske, 2007). High cytoplasmic levels of Ca2+ act as a
second messenger for the activation of signalling pathways and tran-
scription factors that regulate the expression and secretion of cytoki-
nes and other immune regulatory factors (Izquierdo et al, 2014).
Ca2+ release from the ER can be impaired by HCQ (Goldman et al,
2000; Xu et al, 2015; Wu et al, 2017), leading to the inhibition of
intracellular signals. In particular, T-cell and B-cell receptor-
mediated intracellular Ca2+ mobilization from both intracellular
stores and the extracellular milieu is inhibited by HCQ in a dose-
dependent manner (Goldman et al, 2000). This impairment of Ca2+
mobilization is at least partially caused by the reduction of the Ca2+
stored intracellularly and the inability to replenish these intracellular
stores with extracellular Ca2+ (Goldman et al, 2000). This further
enhances its negative impact on the Ca2+-dependent signalling path-
ways (Fig 1C) (Feske, 2007). The precise mechanism of HCQ-induced
reduction of internal Ca2+ mobilization remains unknown. However,
it has been shown that HCQ does not reduce the availability of inosi-
tol 1,4,5-trisphosphate, but rather the binding to its intracellular
receptors that promotes Ca2+ release (Misra et al, 1997).
The impact of CQ and HCQ on the immune system
in autoimmunity
Autoimmunity is characterized by an overreaction of the immune
system (Smith & Germolec, 1999), which is linked to both innate and
adaptive immunity (Mescher, 2016). The innate immune system is
responsible for the initial recognition of pathogens, which is mostly
carried out by antigen-presenting cells (APCs), e.g. dendritic cells,
and eventually triggers the activation of the adaptive immune system
(Mescher, 2016). In particular, when APCs get directly activated
through exposure to pathogen-associated molecular patterns, they
initiate both cell- and antibody-mediated immune responses, which
are mediated by the T and B cells, respectively (Christmas, 2010).
The cell-mediated response is executed by T cells that get activated
by APCs through antigen presentation at their surface via MHC mole-
cules. In contrast, B cells are activated through T helper (Th) cells
and cytokines that are secreted by APCs (Mescher, 2016). Activated B
cells produce and secrete additional pro-inflammatory cytokines and
antibodies to further stimulate the immune reaction (Mescher, 2016).
HCQ and CQ negatively regulate many aspects of these innate
and adaptive immune responses by reducing inflammation, and ulti-
mately the severity of autoimmune diseases (Fig 2).
Inhibition of pro-inflammatory cytokine secretion
Through the inhibition of endosomal TLR signalling, HCQ and CQ
treatment decreases the levels of pro-inflammatory cytokines
produced by peripheral mononuclear cells in the blood, including
IFNc (Van Den Borne et al, 1997), TNFa (Picot et al, 1991; Van Den
Borne et al, 1997; Jang et al, 2006), IL-1 (Picot et al, 1991; Sperber
et al, 1993; Jang et al, 2006), IL-6 (Sperber et al, 1993; Van Den
Borne et al, 1997; Jang et al, 2006) and IL-2 (Landewe et al, 1995).
The reduction of TLR signalling-mediated activation of immune cells
by both drugs consequently decreases the aberrant immune
response and diminishes inflammation symptoms observed in rheu-
matic patients (da Silva et al, 2013). In addition to directly inhibit-
ing endosomal TLR signalling, CQ and HCQ can interfere with the
intracellular signals that lead to both the release of phorbol ester-
induced arachidonic acid and the block of pro-inflammatory cytoki-
nes secretion (e.g. TNFa and IL-1) in mouse macrophages (Bon-
deson & Sundler, 1998). In particular, activation of phospholipase
A2 by phorbol esters, but not by Ca2+, is inhibited by HCQ and CQ,
which blocks the synthesis of arachidonic acid. Furthermore, these
compounds negatively impact the generation of zymosan-induced
formation of inositol phosphates, a product of phospholipase C
activity (Matsuzawa & Hostetler, 1980), suggesting that they have
an inhibitory effect on this enzyme as well (Bondeson & Sundler,
1998). HCQ also inhibits Ca2+-activated K+ channels in macro-
phages, and consequently K+ efflux, which could result in impaired
inflammasome activation and pro-inflammatory cytokine release
(Eugenia Schroeder et al, 2017).
High levels of pro-inflammatory cytokines are a central charac-
teristic of the RA pathogenesis (McInnes & Schett, 2007; Blasius &
Beutler, 2010; Pollard et al, 2013; Schinnerling et al, 2017; Musk-
ardin & Niewold, 2018). In particular, stimulatory cytokines (i.e. IL-
1, IL-6, IL-12, IL-15, IL-17, IL-23 and type I and II IFN for T cells,
and B-cell activating factor (BAFF) for B cells) activate T and B cells,
which in turn produce pro-inflammatory cytokines and autoantibod-
ies, respectively. Pro-inflammatory cytokines contribute to RA
pathogenesis by promoting autoimmunity, maintaining chronic
inflammatory synovitis and stimulating the destruction of joint
tissues. They also play a role in the maturation and activation of
osteoclasts, the cells responsible for breaking down bone tissue
(McInnes & Schett, 2007).
Excessive production of BAFF, a cytokine essential for B-cell
physiology, alters the immune tolerance by contributing to the
maturation and survival of self-reactive B cells, the major source for
autoantibodies contributing to joint inflammation (Mahdy et al,
2014). Reduction of the high BAFF levels in the serum from RA
patients by HCQ (Mahdy et al, 2014) improves symptoms of RADs,
both in animal models and in clinical trials (Sun et al, 2008).
Cytokines like BAFF, TNFa, IFNa and IFNc are also major
contributors to SLE severity, by promoting B-cell survival and
autoantibody production, and contributing to organ inflammation
(Rönnblom & Elkon, 2010). Thus, the modulation of their levels
represents a potential therapeutic avenue (Rönnblom & Elkon,
2010). This is supported by a cohort study showing that treatment
of SLE patients with HCQ results in a decrease of type I IFN levels
and concomitant reduction of disease severity (Willis et al, 2012).
HCQ can also directly affect the production of autoantibodies by B
cells through TLR9 inhibition. Particularly, HCQ interferes with the
differentiation of memory B cells into antibody-producing
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plasmablasts, a subset of B cells, by inhibiting TLR9 activation
(Torigoe et al, 2018).
Although the pathogenesis of pSS is not fully understood yet,
activation of exocrine gland epithelium cells is thought to lead to
the release of pro-inflammatory cytokines such as IFNa and IFNb
(both type I IFN), IL-7 and BAFF, and chemokines (Retamozo
et al, 2018). These factors stimulate further activation of APCs,
but also of T and B cells, which promotes inflammation and
autoimmunity (Retamozo et al, 2018). Only a few studies investi-
gated HCQ administration in pSS patients. Nonetheless, pSS
patients treated with HCQ have a significant lower BAFF levels in
the serum, and an improvement in saliva production (Mumcu
et al, 2013), indicating that this drug might be a promising ther-
apy for pSS as well.
Inhibition of B- and T-cell activation through Ca2+ signalling
Through T-cell receptors (TCRs) on their surface, T cells recognize
antigens that are presented by APCs and get activated (Goldman
et al, 2000). This results in both their proliferation and the release of
various cytokines, including IL-6 and TNFa (Sperber et al, 1993).
One important step in the signalling cascade downstream of TCRs is
the increase of intracellular Ca2+ levels, which is released from inter-
nal Ca2+ storages such as the ER. As previously mentioned, HCQ can
impair the release of Ca2+ from the ER, which consequently inhibits
T-cell activation (Goldman et al, 2000; Xu et al, 2015; Schmidt et al,
2017). HCQ also negatively influences the expression and activity of
CD154 on T cells, which is needed for B-cell activation (Wu et al,
2017; Dewitte et al, 2020). CD154 expression is controlled by the
nuclear factor of activated T cells (NFAT), a transcription factor that
relies on Ca2+ release from the ER (Wu et al, 2017). By impairing
this event, HCQ inhibits NFAT nuclear translocation, resulting in
decreased gene expression of CD154 (Wu et al, 2017). Altogether,
these studies show that blocking Ca2+ release from the ER by HCQ
leads to a multilevel inhibition of T- and B-cell activation, thereby
hindering the immune response (Fig 2).
Modulation of Th17 and Treg populations
Alterations in autophagic activity play an important role in the
pathophysiology of T- and B-cell-mediated autoimmunity (Weindel
et al, 2015; van Loosdregt et al, 2016; Alessandri et al, 2017;
Mocholi et al, 2018; Zhang et al, 2019). In this context, autophagy
is required to maintain cellular homeostasis in T cells (An et al,
2017c) and autophagy deficiency impairs MHC class II presentation
and contributes to the generation of autoreactive T cells by thymic
epithelial cells (Levine et al, 2011). Moreover, plasma cells require
autophagy to sustain immunoglobulin production and B-cell devel-
opment (Wu & Adamopoulos, 2017). An imbalance within the T-cell
populations, more specifically an increase in the number of Th17
cells and a decrease in that of Treg cells, has been linked to patho-
genesis of autoimmune diseases (Yang et al, 2011a; Jadidi-Niaragh
& Mirshafiey, 2012; Álvarez-Rodrı́guez et al, 2019), including SLE
(An et al, 2017c; Álvarez-Rodrı́guez et al, 2019). This imbalance
leads to an increased secretion of pro-inflammatory cytokines such
as IL-17 and IL-6, and a reduction of the levels of circulating factors
like TGF-b, which suppresses inflammation and autoimmunity (An
et al, 2017c; Geng et al, 2020). This latter effect can be dampened
with HCQ and CQ, as those drugs rebalance the Th17/Treg ratio (An
et al, 2017c; Yang et al, 2018; Álvarez-Rodrı́guez et al, 2019; Park
et al, 2019; Geng et al, 2020). Mechanistically, this could be caused
by an alteration of autophagy, as an induction of this process is
observed in SLE patients (An et al, 2017c). Thus, An and colleagues
thought to suppress hyperactivated autophagy by administrating
HCQ to lupus MLR/pr mice, an animal model for SLE. In addition to
lowering autophagic activity in this model, HCQ rebalanced Th17
and Treg cell numbers, which led to a decrease in pro-inflammatory
cytokine levels (Fig 2) and a concomitant augmentation of anti-
inflammatory cytokines, resulting in the suppression of the autoim-
mune response (An et al, 2017c). Moreover, CQ positively regulates
Treg differentiation by stimulating transcriptional activity of Nurr1
and FOXP3, while simultaneously suppressing Th17 differentiation
and gene expression (Álvarez-Rodrı́guez et al, 2019; Park et al,
2019). More evidence that Th17 cells play a central role in RA and
SLE pathogenesis comes from the detection of IL-6, IL-17 and IL-22
in synovial fluids from patients suffering from those diseases (Lub-
berts et al, 2005; da Silva et al, 2013). High levels of these cytokines
correlate with synovial inflammation, T-cell activation and the
osteoclast activity upregulation causing bone erosion (da Silva et al,
2013). Administration of HCQ reduces Th17 cell activation and
consequently production of IL-6, IL-17 and IL-22 (da Silva et al,
2013; Yang et al, 2018).
Impact of NOX inhibition on the immune system
NOX inhibition by HCQ impairs the production of pro-inflammatory
cytokines and the correct distribution of TLR8, thereby dampening
the immune response (Müller-Calleja et al, 2017). This inhibition
also positively affects nitric oxide (NO) bioavailability (Gómez-
Guzmán et al, 2014). NO is involved in a multitude of physiologic
functions, including the regulation of blood vessel tone and vasodi-
lation, and is rapidly inactivated by ROS (Nagy et al, 2010). In SLE
patients, NO bioavailability is severely lowered by high ROS levels,
particularly O2, resulting in endothelial dysfunction (Griendling &
Alexander, 1997; Landmesser & Harrison, 2001; Gómez-Guzmán
et al, 2014). By blocking NOX, the major producer of O2 in the
vascular wall, HCQ treatment reduces ROS levels and helps to
prevent endothelial dysfunction in a mouse model for SLE (Gómez-
Guzmán et al, 2014). In agreement with this concept, NOX inhibi-
tion by HCQ reduces thrombus formation, which is a well-known
clinical manifestation in SLE, in a venous thrombus mouse model
(Müller-Calleja et al, 2017; Miranda et al, 2019) (Fig 2).
Thus, at the cellular level, HCQ and CQ inhibit antigen presenta-
tion, NOX signalling, B- and T-cell activation, and rebalance Treg/
Th17 cell ratio. These multifaceted effects on different immune cells
synergistically result in a decreased production and release of pro-
inflammatory cytokines, a common hallmark of RADs (Fig 2).
Clinical impact of HCQ on RADs
HCQ is administered orally in tablet form as hydroxychloroquine
sulphate (Pastick et al, 2020). It is absorbed in the gastrointestinal
tract (Mclachlan et al, 1994) before being widely distributed
throughout the body to muscles, liver, spleen, lungs, kidneys, pitu-
itary and adrenal glands, and tissues that contain melanin (Haładyj
et al, 2018). Daily dosage of HCQ ranges from 200 to 600 mg for
RADs, from 200 to 400 mg for dermatological disorders (Ben-Zvi
et al, 2012), from 200 to 1,200 mg in cancers (Chude & Amaravadi,
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2017) and from 200 to 800 mg for various infectious diseases. Its
half-life in the body ranges between 40 and 50 days (Mclachlan
et al, 1994), and 30–40% of HCQ is protein-bound (Furst, 1996),
resulting in 60–70% unbound, pharmacologically active drug (Rang
et al, 2016). The majority of HCQ is excreted through the kidneys,
while the rest is metabolized by the liver or excreted through faeces
(Furst et al, 1999; Haładyj et al, 2018). Contraindications for taking
HCQ are a history of retinopathy or visual field changes, hypersensi-
tivity to 4-aminoquinoline compounds and long-term therapies in
children (https://www.fda.gov/). HCQ is, however, considered safe
during pregnancy (Kaplan et al, 2016; Haładyj et al, 2018).
HCQ ameliorates classical RAD symptoms, such as skin problems
and joint pain, predominantly by decreasing the inflammation reac-
tion in patients (Fig 3). In SLE, HCQ is given to patients as either a
single or a combinatorial therapy together with steroids and
immunosuppressive drugs, to improve patients’ life expectancy by
reducing lupus flares and accrual of organ damage (Ponticelli &
Moroni, 2017). Case studies have revealed that HCQ treatment
reduces SLE symptoms and improves long-term survival of patients,
while individuals not treated with HCQ have an increased risk of
severe SLE exacerbations (James et al, 2007; Ruiz-Irastorza et al,
2010; Willis et al, 2012).
Similarly, HCQ treatment produces significant clinical improve-
ment and functional capacity in RA patients (Smolen et al, 2014;
Haładyj et al, 2018). In RA, prevention of cartilage degradation,
which causes joint destruction, is an important aspect of the thera-
peutic approach (Kumar & Clark, 2012). Cartilage degradation is
mostly caused by pro-inflammatory cytokines, such as IL-1, IL-17
and TNFa, and their production can be repressed by HCQ treatment
(Picot et al, 1991; Sperber et al, 1993; Van Den Borne et al, 1997;
Jang et al, 2006; McInnes & Schett, 2007; da Silva et al, 2013). In
vitro experiments have also established that CQ inhibits proteogly-
can turnover (Fulkerson et al, 1979; Ackerman et al, 1981; Schug &
Kalbhen, 1995; Rainsford et al, 2015), and early autoradiographic
studies following tritium-labelled HCQ have revealed that this drug
accumulates in the cartilage of mice (Cecchi & Porzio, 1964). These
findings and its water-soluble properties led to the proposition that
HCQ accumulates in the cartilage by binding acidic proteoglycans
and protecting them from degradation by proteolytic enzymes
(Rainsford et al, 2015). Although an early study pointed out that CQ
and HCQ can indeed inhibit cartilage breakdown, slowing down the
disease progression and preventing further joint damage in RA
patients (Julkunen et al, 1976), more recent investigations could not
confirm a positive effects on joint damage (Sanders, 2000; Smolen
et al, 2014; Haładyj et al, 2018).
The therapeutic benefits of HCQ administration on pSS classical
symptoms, e.g. sicca symptoms, remain controversial; some studies
documented beneficial effects (Tishler et al, 1999; Rihl et al, 2009;
Yavuz et al, 2011; Mumcu et al, 2013), while others reported none
(Gottenberg et al, 2014; Yoon et al, 2016; Wang et al, 2017). HCQ
treatment, however, ameliorates extraglandular symptoms (Fox et al,
1996; Demarchi et al, 2017), and according to the Sjögren’s
Syndrome Foundation’s clinical practice guidelines (https://www.sjo
grens.org/), disease-modifying anti-rheumatic drugs are recom-
mended to treat musculoskeletal pain, with HCQ being the
therapeutic approach of choice (Carsons et al, 2015). HCQ also
reduces immunological alterations of pSS, such as decreased levels of
immunoglobulins, erythrocyte sedimentation rate, serology and IL-6
production (Tishler et al, 1999; Yavuz et al, 2011; Mumcu et al,
2013). Furthermore, in a retrospective analysis, HCQ administra-
tion to pSS patients significantly improved saliva production (Rihl
et al, 2009). This improvement was more pronounced in patients
who were positive for autoantibodies against anti-a-fodrin, an
intracellular filamentous cytoskeleton protein. While the cause for
this difference remains unknown, a possible explanation is that
HCQ could improve saliva production by decreasing elevated
levels of cholinesterase, an enzyme that counteracts saliva produc-
tion (Dawson et al, 2005).
HCQ and CQ in non-rheumatologic diseases
Anti-viral effects
The anti-viral function of HCQ and CQ has mainly been linked to
their ability to increase the pH of the endosomal system and the
trans-Golgi network (TGN) (Savarino et al, 2003). Thus, these drugs
are able to inhibit cell entry of numerous viruses, as a low endoso-
mal pH is required for the fusion of endocytosed virions with the
limiting membrane of endosomes. In this context, CQ and HCQ
decrease replication of viruses such as dengue virus (DENV2),
chikungunya virus, hepatitis A and C virus, influenza A virus, Zika
virus, severe acute respiratory syndrome coronavirus (SARS-CoV)
and Borna disease virus in cellular models (Bishop, 1998; Gonzalez-
Dunia et al, 1998; Keyaerts et al, 2004; Vincent et al, 2005; Blan-
chard et al, 2006; De Clercq, 2006; Eng et al, 2006; Di Trani et al,
2007; Sourisseau et al, 2007; Khan et al, 2010; Ashfaq et al, 2011;
Boonyasuppayakorn et al, 2014; Farias et al, 2015; Delvecchio et al,
2016; Shiryaev et al, 2017). For some viral structural proteins, a
maturation step involving post-translational modification and/or
processing in the TGN is crucial for their function and ultimately for
the assembly of infectious viral particles, e.g. glycosylation of HIV
gp120 (Tsai et al, 1990; Savarino et al, 2004) or cleavage of the
DENV2 prM protein (Randolph et al, 1990). Glycosylation in the
TGN is also required for the correct assembly of ACE2, the entry
receptor for SARS-CoV (Vincent et al, 2005). Thus, HCQ and CQ
contribute to inhibit viral infections by neutralizing the pH of intra-
cellular organelles, interfering with important processes required for
viral life cycle.
Although HCQ and CQ have shown beneficial therapeutic effects
in animal models for DENV2, hepatitis C virus, avian influenza A
virus, Zika virus and SARS-CoV infections, clinical trials have so far
failed to conclusively prove their anti-viral potential in humans
(Rodrigo et al, 2020; Fragkou et al, 2020; McKee et al, 2020). This
might be due to the fact that drug concentrations required to de-
acidify intracellular compartments cannot easily be reached in
humans (Al-Bari, 2017). Therefore, neither HCQ nor CQ is currently
recommended as anti-viral drugs (Rodrigo et al, 2020). During the
SARS-CoV-2 pandemic in 2020, the need to find an effective medica-
tion has brought major attention to HCQ and CQ due to their ability
to both inhibit viral infections and dampen the massive cytokine
response that is observed in SARS-CoV-2-infected patients (Badgujar
et al, 2020; Ibáñez et al, 2020; Moore & June, 2020). The effective-
ness of HCQ and CQ against SARS-CoV-2, however, has so far not
been proven in humans, and the results at the time that this review
was completed were still controversial (Boulware et al, 2020;
Fragkou et al, 2020).
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Anti-cancer therapy
CQ and HCQ are being increasingly used in clinical trials to treat
cancer (https://clinicaltrials.gov/). Because high doses are required
to achieve anti-tumoural effects in monotherapies, they are often
used in combination with radiotherapy and/or other chemothera-
peutical drugs (Plantone & Koudriavtseva, 2018). We briefly discuss
here possible mechanisms of action for HCQ and CQ in cancer. For
a more detailed discussion on this topic, more specific reviews are
available (Manic et al, 2014; Pascolo, 2016; Levy et al, 2017; Shi
et al, 2017; Verbaanderd et al, 2017).
Elevated autophagic activity is crucial for tumour cell survival
and growth as it supplies the high demand of nutrients within a
developed tumour (Amaravadi et al, 2016). This is especially rele-
vant for autophagy-dependent cancers that rely on this pathway
when faced with metabolic stress. Consequently, HCQ or CQ treat-
ment has been successful in regressing the growth of some of those
cancers in preclinical studies (e.g. with RAS pathway mutations
(Guo et al, 2011; Lock et al, 2011), such as specific pancreatic
cancers (Mancias & Kimmelman, 2011; Yang et al, 2011b; Sousa
et al, 2016), or BRAF-driven tumours (Levy et al, 2014; Strohecker
et al, 2013; Xie et al, 2015). The effectiveness of HCQ and CQ in
cancer therapy is, however, controversial. In animal models, HCQ
dosages are often 50 mg/kg/day or higher, which is too high to be
administered in humans (Pascolo, 2016), and with lower dosages,
autophagy is not sufficiently inhibited to achieve tumour regression
(Pascolo, 2016). Moreover, some cancer cells (e.g. derived from
breast tumours or melanomas or KRAS-driven cancer cell lines) have
shown CQ-mediated cell growth inhibition that was independent of
autophagy (Maycotte et al, 2012; Maes et al, 2014; Eng et al, 2016).
Various cancer cells express high levels of TLR9, e.g. breast and
prostate cancer cells (Merrell et al, 2006; Verbaanderd et al, 2017),
which is linked to cancer invasiveness in vitro and associated with
poor prognosis (Väisänen et al, 2013; Verbaanderd et al, 2017).
TLR9-mediated NF-jB signalling is required for cancer cell migra-
tion and proliferation in gastric cancer cell models, which is inhib-
ited by CQ (Zhang et al, 2015). The exact molecular mechanism of
TLR9 signalling inhibition in cancer cells remains unknown.
Another mechanism by which HCQ affects cancer growth is by
modulating the immune system. Tumour-associated macrophages
(TAMs), which are phenotypically described as M2 macrophages,
play a role in promoting tumour growth and immune escape,
angiogenesis and metastasis (Mantovani et al, 2017; Li et al,
2018). In contrast, tumour killing macrophages (M1 macrophages)
have an opposite effect and are activated by cytokines such as
IFNc, which are released from T cells (De Palma & Lewis, 2013;
Ostuni et al, 2015). Interestingly, in a melanoma-bearing mouse
model, intraperitoneal injection of 75 mg/kg CQ effectively inhib-
ited melanoma growth in a T-cell-dependent manner, and
prolonged animal survival (Chen et al, 2018). Mechanistically, CQ
can switch TAMs into M1 macrophages by raising lysosomal pH,
and thereby mobilizing lysosomal Ca2+ through upregulation of
the lysosomal Ca2+ channel MUCOLIPIN1. The release of lysoso-
mal Ca2+ then activates the p38 and NF-jB pathways, but also the
transcription factor EB, resulting in an enhanced anti-tumour T-cell
response (Chen et al, 2018). By stimulating the T-cell-mediated
immune response and simultaneously decreasing immune inhibi-
tory cells, including TAMs and Tregs, and cytokines such as TGF-b
and IL-10, CQ treatment reduced breast cancer growth and
prolonged mice survival in a breast xenograft model (Zhang et al,
2017). Another important aspect of anti-cancer immunity is the
activation of immune cells by sensing danger signals (e.g.
HMGB1). Danger signals are subsequently recognized by receptors,
such as TLR4 on dendritic cells (Apetoh et al, 2007). One function
of TLR4 is to preserve engulfed tumour antigens from enhanced





























Figure 3. Beneficial and side effects caused by HCQ in RAD patients.
In RADs, HCQ treatment predominantly alleviates the symptoms (purple boxes)
by inhibiting the production and release of pro-inflammatory cytokines. As a
consequence, HCQ diminishes skin conditions. There are also indications that
HCQ both decreases cartilage degradation and consequently reduces joint and
muscle pain, and helps to restore saliva production. Usage of HCQ can cause side
effects (orange boxes); the most common are gastrointestinal disturbances, skin
discoloration, cutaneous eruptions and elevated muscle enzymes, whereas
retinopathy, cardiac myopathy and myotoxicity are rare, but severe.
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antigen presentation capacity in TLR4-deficient dendritic cells can
be restored by CQ, possibly by raising lysosomal pH, which
contributed to tumour size reduction in a tlr4/ thymoma mouse
model (Apetoh et al, 2007). Along these lines, CQ reduced breast
cancer growth in mice after irradiation by enhancing apoptotic and
immunogenic tumour cell death (Ratikan et al, 2013). The
enhanced immune response was attributed to a decreased degrada-
tion of tumour antigens in dendritic cells, resulting in an increased
antigen presentation (Ratikan et al, 2013).
HCQ and CQ can also inhibit CXCL12/CXCR4 signalling, which is
involved in chemotaxis and adhesion of tumour cells and of growth
factors secretion that are key for cancer progression (Sun et al,
2010; Kim et al, 2012; Verbaanderd et al, 2017). Moreover, HCQ
and CQ interfere with the activation of growth-promoting pathways
in cancer stem cells, thereby suppressing the regrowth of tumours
(Li et al, 2008; Balic et al, 2014; Choi et al, 2014).
Multiple reports further describe the mechanisms by which CQ
triggers cell death in tumour cells. CQ induces apoptosis of cancer
cells by either stimulating the mitochondrial apoptotic pathway (Du
Jiang et al, 2010) or activating the p53-dependent transcription of
pro-apoptotic genes (Zhou et al, 2002; Loehberg et al, 2007, 2012;
Maclean et al, 2008; Kim et al, 2010; Bieging et al, 2014). Addition-
ally, several studies have suggested that CQ intercalates into DNA
and disturbs chromatin topology (O’Brien et al, 1966; Sternglanz
et al, 1969; Field et al, 1978; Yin et al, 2003), which could lead to
an impairment in DNA repair mechanisms, and in turn cause DNA
damage and enhance cell death (Michael & Williams, 1974; Liang
et al, 2016; Weyerhäuser et al, 2018).
Besides directly targeting tumour cells, CQ also affects tumour
angiogenesis by altering endothelial cell functionality. CQ adminis-
tration leads to NOTCH1 accumulation in endothelial cell endo-
somes, stimulating the downstream signalling that leads to tumour
vessel normalization, and resulting in reduced tumour invasion
and metastasis (Maes et al, 2014). Therefore, CQ also improves
the delivery and efficacy of other chemotherapeutics (Maes et al,
2014).
HCQ and CQ thus show potential in inhibiting tumour growth
and modulating tumour immune response through various mecha-
nisms. It is, however, important to reiterate that the doses used to
achieve relevant effects in cancer therapies are often substantially
higher than the doses used to treat RADs. Moreover, when treating
cancer or viral infections, one has to keep in mind that HCQ and CQ
also have immune suppressive functions that could negatively influ-
ence its beneficial effect for the patients.
Side effects of HCQ in RADs
Side effects of HCQ treatment are rare, but nonetheless exist, and
can be very serious, especially during prolonged administration
(Haładyj et al, 2018). In Table EV1, we provide a comprehensive
overview of the known side effects caused by HCQ in RADs and
their prevalence. Overall, the most common side effects in RAD
patients taking HCQ or CQ are gastrointestinal disturbances, skin
discolorations, cutaneous eruptions and elevated muscle enzymes.
Although rare, retinopathy, neuromuscular and cardiac toxicities
(Fig 3) are the most serious and life-threatening side effects poten-
tially triggered by HCQ (Plantone & Koudriavtseva, 2018).
Retinopathy
Prolonged administration of HCQ or CQ can cause retinopathy and
loss of retinal function that, when ignored, can result in permanent
vision loss (Jorge et al, 2018). The primary site of toxicity in the
retina is the photoreceptor layer, with secondary degeneration
occurring later in retinal pigment epithelium (RPE) cells (De Sister-
nes et al, 2015; Yusuf et al, 2017). Some studies offer a potential
explanation for this severe side effect.
By inhibiting the lysosomal degradation capacity and possibly
endocytosis in RPE cells, HCQ and CQ are preventing the degrada-
tion of old and spent outer segments of photoreceptors in the RPE, a
process that is required to maintain its function and preserve vision
(Kevany & Palczewski, 2010; Yusuf et al, 2017). Furthermore, HCQ
entrapment in the RPE might lead to an accumulation of lipofuscin,
which is associated with photoreceptor function impairment and
consequent vision loss (Kevany & Palczewski, 2010; Yusuf et al,
2017). It has been speculated that, due to this entrapment, retinopa-
thy still continues in some cases after cessation of HCQ treatment
(Michaelides et al, 2011). Accumulation of CQ in the pigmented
ocular tissue, which comprises RPE cells, the iris, the choroid and
the ciliary body, and eventually in the retina, was also observed in
rhesus monkeys when CQ was administered for 52 months (Rosen-
thal et al, 1978). This caused an initial damage to the photorecep-
tors and the ganglion cells, followed by a disruption of both the RPE
and choroid, which ultimately led to visual impairments and
retinopathy (Rosenthal et al, 1978).
High levels of HCQ inhibit the function of the organic anion
transporting polypeptide 1A2 (OATP1A2), a plasma membrane
importer expressed in many tissues, including RPE cells (Xu et al,
2016). In particular, OATP1A2 transports all-trans-retinol (atROL), a
retinol precursor essential for the classic visual cycle (Chan et al,
2015), into RPE cells. By blocking this transporter, HCQ causes an
extracellular accumulation of atROL and disrupts the classic visual
cycle (Xu et al, 2016).
Cardiac side effects and myotoxicity
HCQ can cause acute and chronic cardiac adverse effects (Chatre
et al, 2018). Acute adverse effects are linked to a very high dose of
HCQ, which provokes a block of Na+ and Ca2+ channels. This inhi-
bition can lead to membrane-stabilization effects in cardiac muscle
cells, which in turn causes conduction disturbances with atrioven-
tricular block and QRS interval widening (White, 2007). Chronic
adverse effects are connected to long-term treatment with a high
cumulative dose of HCQ (Chatre et al, 2018). As described above,
HCQ treatment impairs the degradative activity of lysosomes, which
leads to an accumulation of material such as glycogen and phospho-
lipids in their interior (Chatre et al, 2018). In myocytes, this causes
a vascularization of the cytoplasm and myofibrillar disorganization,
which contributes to the development of cardiac myopathy and
myocardial fibrosis (Yogasundaram et al, 2014). This phenomenon
can also be seen in the Fabry and Danon lysosomal storage diseases,
which have similar phenotypes (Roos et al, 2002; D’souza et al,
2014; Chatre et al, 2018). Moreover, HCQ-mediated accumulation of
autophagosomes in muscles and peripheral nerves can lead to
myotoxicity or myotoxicity combined with peripheral nerve
dysfunction (Shukla et al, 2019). Notably, HCQ and CQ also have
proarrhythmic activity (Landmesser & Harrison, 2001; Khobragade
et al, 2013; Chansky & Werth, 2017; Naksuk et al, 2020), which is
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of particular importance because of the potential use of this drug to
treat COVID-19 patients. These patients are burdened by arrhythmic
events, and consequently, HCQ and CQ could worsen this pathologi-
cal feature. It is still under investigation whether this proarrhythmic
activity is caused by SARS-CoV-2 infection and whether HCQ and
CQ are influencing it (Lazzerini et al, 2020).
Conclusions
HCQ is nowadays widely used for the treatment of RADs and has
shown great success in improving the quality of life of many patients.
Over the years, research on the molecular and cellular mode of action
of HCQ (and CQ) revealed that this compound modulates molecular
processes and cellular responses in multiple ways. At least four mech-
anisms of action that, directly or indirectly, influence the immune
system by synergistically dampening pro-inflammatory responses,
have been described. Although lysosomal inhibition and autophagy
impairment are the most studied, HCQ also influences other impor-
tant immune regulatory pathways by inhibiting specific steps, such as
activation of endosomal TLR-, cGAS and NOX signalling and Ca2+
mobilization for the ER. The beneficial therapeutic effect of HCQ in
RADs probably lies in its multifaceted properties, which also makes it
a promising candidate in other medical fields, such as oncology (Ono-
rati et al, 2018) and microbiology (Savarino et al, 2003; Cortegiani
et al, 2020; Yao et al, 2020).
Generally, HCQ is considered a safe drug with low prevalence of
side effects. These side effects nevertheless exist and can impact the
life of a patient tremendously. Among them, the most severe, i.e.
retinopathy and cardiomyopathy, is linked to the induced lysosomal
activity inhibition. This suggests that the unwanted negative effects
of HCQ could be due to its lysosomotropic properties. In this context,
it has been reported that the effect of HCQ on endosomal and lysoso-
mal pH at therapeutic concentrations is negligible (Kuznik et al,
2011) and that the pH changes observed in vitro might not reflect the
in vivo reality. Therefore, a higher dose of HCQ (or a higher cumula-
tive dose) could lead to a pH increase in the compartments of the
endolysosomal system and thus cause more side effects (Latasiewicz
et al, 2017; Jorge et al, 2018). The well-documented list of side effects
caused by HCQ during the treatment of RADs should be considered
when using HCQ to treat other pathologies such as cancer (Onorati
et al, 2018), neurodegenerative disorders (Hedya et al, 2019), meta-
bolic diseases (Pasquier, 2016) and microbial infections (Savarino
et al, 2003), especially since treatment of some pathologies requires
high HCQ doses (Leung et al, 2015).
While the search for a unifying mechanism of action for HCQ is
tempting, current knowledge shows that this small molecule has more
than a single target. As a result, future research should aim at identify-
ing potential additional cellular and organismal pathways specifically
modulated by HCQ. The mechanisms by which HCQ causes side
effects could also provide important information. Increasing our under-
standing of HCQ mode of action would improve patient outcome by
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